Thursday, October 26, 2023 10:25:21 PM
Now, when the share price is in $5-6 area, I would like to discuss with you and member of this very active board the general question about CEOs of public companies.
To tell the truth, I don't think that Dr. Missling is a very bad CEO. I think he is trying to do his best - hiring a former FDA specialist, partnership with Partex Group for AI development of drugs - these are his positive achievements. That is a pity, as a result of unskillful presentations of results of phase 2b/3 trial of blarcamesine we came to this pitiful situation.
And now my general question. My impression is that CEOs of public companies think that they are owners of companies and will remain CEO forever and can do anything they want.
Can you or anybody else explain why there are incentives for them? Is their salary is not good enough incentive? Again, my impression is that they introduce incentives for themselves. Of course, formally, this is not a case but only formally.
The largest "public company" is our country. And Presidents have their salary and no incentives. Let's consider public universities. There is no incentives there as well.
Dr. Missling bought recently half a million of shares with $1.7 price. Was this an incentive? His salary is $700,000. In usual life, as a university professor he could earn $150 K - 200 K. Do you agree this is a big difference? Of course, I am wrong if Dr. Missling invented blarcamesine.
Next question is how long a CEO of any public company can have this position? And again, presidents or chancellors of public universities have their position no more than eight years.
There are several other questions, however, I think it will be too much to ask them just now.
Please don't reply with your famous "Complete Nonsense", just give your point of view.
To tell the truth, I don't think that Dr. Missling is a very bad CEO. I think he is trying to do his best - hiring a former FDA specialist, partnership with Partex Group for AI development of drugs - these are his positive achievements. That is a pity, as a result of unskillful presentations of results of phase 2b/3 trial of blarcamesine we came to this pitiful situation.
And now my general question. My impression is that CEOs of public companies think that they are owners of companies and will remain CEO forever and can do anything they want.
Can you or anybody else explain why there are incentives for them? Is their salary is not good enough incentive? Again, my impression is that they introduce incentives for themselves. Of course, formally, this is not a case but only formally.
The largest "public company" is our country. And Presidents have their salary and no incentives. Let's consider public universities. There is no incentives there as well.
Dr. Missling bought recently half a million of shares with $1.7 price. Was this an incentive? His salary is $700,000. In usual life, as a university professor he could earn $150 K - 200 K. Do you agree this is a big difference? Of course, I am wrong if Dr. Missling invented blarcamesine.
Next question is how long a CEO of any public company can have this position? And again, presidents or chancellors of public universities have their position no more than eight years.
There are several other questions, however, I think it will be too much to ask them just now.
Please don't reply with your famous "Complete Nonsense", just give your point of view.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
